Targeted Removal of Migratory Tumor Cells by Functionalized Magnetic Nanoparticles Impedes Metastasis and Tumor Progression

• Chambers AF , GroomAC, MacDonaldIC: Metastasis: dissemination and growth of cancer cells in metastatic sites.Nat. Rev. Cancer2(8), 563–572 (2002).
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB , ZujewskiJA: CNS metastasis: an old problem in a new guise.Clin. Cancer Res.13(6), 1644–1647 (2007).
   PubMed Web of Science ®Google Scholar
• Barnholtz-Sloan JS , SloanAE, DavisFG, VigneauFD, LaiP, SawayaRE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system.J. Clin. Oncol.22(14), 2865–2872 (2004).
   PubMed Web of Science ®Google Scholar
• Roodman GD : Mechanisms of bone metastasis.N. Engl. J. Med.350(16), 1655–1664 (2004).
   PubMed Web of Science ®Google Scholar
• Herzog TJ , PothuriB: Ovarian cancer: a focus on management of recurrent disease.Nat. Clin. Pract. Oncol.3(11), 604–611 (2006).
   PubMedGoogle Scholar
• Koolpe M , DailM, PasqualeEB: An ephrin mimetic peptide that selectively targets the epha2 receptor.J. Biol. Chem.277(49), 46974–46979 (2002).
   PubMed Web of Science ®Google Scholar
• Scarberry KE , DickersonEB, McDonaldJF, ZhangZJ: Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells.J. Am. Chem. Soc.130(31), 10258–10262 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang L , YangN, GarciaJRCet al.: Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.Am. J. Pathol.161(6), 2295–2309 (2002).
   PubMed Web of Science ®Google Scholar
• Demicheli R , RetskyMW, HrusheskyWJM, BaumM: Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures.Nat. Clin. Pract. Oncol.4(12), 699–710 (2007).
   PubMedGoogle Scholar
• Savage P , StebbingJ, BowerM, CrookT: Why does cytotoxic chemotherapy cure only some cancers?Nat. Clin. Pract. Oncol.6(1), 43–52 (2009).
   PubMedGoogle Scholar
• Meads MB , GatenbyRA, DaltonWS: Environment-mediated drug resistance: a major contributor to minimal residual disease.Nat. Rev. Cancer9(9), 665–674 (2009).
   PubMed Web of Science ®Google Scholar
• Di Fiore F , Van Cutsem E: Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract. Res. Clin. Gastroenterol.23(1), 113–124 (2009).
   PubMed Web of Science ®Google Scholar
• Widder KJ , SenyeiAE, ScarpelliDG: Magnetic microspheres: a model system for site specific drug delivery in vivo.Proc. Soc. Exp. Biol. Med.158(2), 141–146 (1978).
   PubMed Web of Science ®Google Scholar
• Mahmoudi M , SimchiA, ImaniMet al.: A new approach for the in vitro identification of the cytotoxicity of superparamagnetic iron oxide nanoparticles.Colloids Surf. B Biointerfaces75, 300–309 (2010).
   PubMed Web of Science ®Google Scholar
• Binhi V : Do naturally occurring magnetic nanoparticles in the human body mediate increased risk of childhood leukaemia with EMF exposure.Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med.84(7), 569–579 (2008).
   Google Scholar
• Sadauskas E , DanscherG, StoltenbergM, VogelU, LarsenA, WallinH: Protracted elimination of gold nanoparticles from mouse liver.Nanomedicine5, 162–169 (2009).
   PubMed Web of Science ®Google Scholar
• Fent GM , CasteelSW, KimDYet al.: Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine.Nanomedicine5, 128–135 (2009).
   PubMed Web of Science ®Google Scholar
• Scarberry KE , DickersonEB, ZhangZJ, BenignoBB, McDonaldJF: Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles.Nanomedicine6(3), 399–408 (2010).
   PubMed Web of Science ®Google Scholar
• Liu C , ZouB, RondinoneAJ, ZhangZJ: Chemical control of superparamagnetic properties of magnesium and cobalt spinel ferrite nanoparticles through atomic level magnetic couplings.J. Am. Chem. Soc.122(26), 6263–6267 (2000).
   Web of Science ®Google Scholar
• Fields GB , NobleRL: Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.Int. J. Pept. Protein Res.35(3), 161–214 (1990).
   PubMedGoogle Scholar
• Stehle JR , WillinghamMC, LinK, CuiZ: A non-terminal method for frequent collection of mouse circulating proteins by peritoneal lavage.Anal. Biochem.349(1), 162–164 (2006).
   PubMed Web of Science ®Google Scholar
• Szczesny G , VeihelmannA, MassbergS, NolteD, MessmerK: Long-term anaesthesia using inhalatory isoflurane in different strains of mice-the haemodynamic effects.Lab. Anim.38(1), 64–69 (2004).
   PubMedGoogle Scholar
• Rowe JW , SchneiderEL. Handbook of the Biology of Aging (4th Edition). Academic Press, Orlando, FL, USA (1996).
   Google Scholar
• Roby KF , TaylorCC, SweetwoodJPet al.: Development of a syngeneic mouse model for events related to ovarian cancer.Carcinogenesis21(4), 585–591 (2000).
   PubMed Web of Science ®Google Scholar
• Hoskins WJ : Prospective on ovarian cancer: why prevent?J. Cell. Biochem. (Suppl. 23), 189–199 (1995).
   Web of Science ®Google Scholar
• Chien JR , AlettiG, BellDA, KeeneyGL, ShridharV, HartmannLC: Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.J. Cell. Biochem.102, 1117–1129 (2007).
   PubMed Web of Science ®Google Scholar
• Tian X , SongS, WuJ, MengL, DongZ, ShouC: Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell mgc803.Biochem. Biophys. Res. Commun.286, 505–512 (2001).
   PubMed Web of Science ®Google Scholar
• Herold-Mende C , SteinerHH, AndiTet al.: Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells.Lab. Invest.79, 1573–1582 (1999).
   PubMed Web of Science ®Google Scholar
• Dias S , HattoriK, ZhuZet al.: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.J. Clin. Invest.106, 511–521 (2000).
   PubMed Web of Science ®Google Scholar
• Santin AD , HermonatPL, RavaggiA, CannonMJ, PecorelliS, ParhamGP: Secretion of vascular endothelial growth factor in ovarian cancer.Eur. J. Gynaecol. Oncol.20, 177–181 (1999).
   PubMed Web of Science ®Google Scholar
• Thaker PH , DeaversM, CelestinoJet al.: Epha2 expression is associated with aggressive features in ovarian carcinoma.Clin. Cancer Res.10, 5145–5150 (2004).
   PubMed Web of Science ®Google Scholar
• Pazdur R : End points for assessing drug activity in clinical trials.Oncologist13(Suppl. 2), 19–21 (2008).
   PubMedGoogle Scholar
• Di Leo A , BleibergH, BuyseM: Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported Phase III trials in colorectal and breast cancer.J. Clin. Oncol.21(10), 2045–2047 (2003).
   PubMed Web of Science ®Google Scholar
• Mantel N : Evaluation of survival data and two new rank order statistics arising in its consideration.Cancer Chemother. Rep.50(3), 163–170 (1966).
   PubMedGoogle Scholar
• Iglewicz B , HoaglinDC: How to detect and handle outliers.American Society for Quality Control,16 (1993).
   Google Scholar
• Jemal A , SiegelR, WardEet al.: Cancer statistics.CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Alvero AB , ChenR, FuHet al.: Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance.Cell Cycle8(1), 158–166 (2009).
   PubMed Web of Science ®Google Scholar
• Smith EM , JaysonGC: The current and future management of malignant ascites.Clin. Oncol. (R. Coll. Radiol).15(2), 59–72 (2003).
   PubMed Web of Science ®Google Scholar
• Roberts PC , MottilloEP, BaxaACet al.: Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model.Neoplasia7(10), 944–956 (2005).
   PubMed Web of Science ®Google Scholar

Website

• GraphPad www.graphpad.com
   Google Scholar